|
|||||
|
|

Online health insurance comparison site eHealth (NASDAQ:EHTH) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 7.7% year on year to $60.78 million. The company’s full-year revenue guidance of $545 million at the midpoint came in 2.5% above analysts’ estimates. Its non-GAAP loss of $0.80 per share was 35.9% above analysts’ consensus estimates.
Is now the time to buy EHTH? Find out in our full research report (it’s free).
eHealth’s second quarter saw revenue exceed Wall Street’s expectations, with the market reacting positively to the company’s ability to adapt in a challenging environment. Management attributed this performance to stronger-than-anticipated Medicare Advantage enrollments and improved member retention, which drove favorable tail revenue and lifetime value metrics. CEO Fran Soistman noted that the company navigated regulatory changes limiting dual-eligible enrollments by shifting focus to insurance products that can be sold year-round and by implementing operational adjustments within the telesales organization. Soistman highlighted, “We successfully navigated benefit plan cancellations and carrier market exits, which enabled us to continue offering high-quality plan options across all of our key markets.”
Looking forward, eHealth’s updated guidance is shaped by expectations for a volatile Medicare Annual Enrollment Period (AEP) and industry-wide shifts in broker commissions. Management emphasized that the improved full-year outlook does not yet fully incorporate recently announced, more favorable commission rates for 2026. Soistman explained, “We have not incorporated any AEP-related impacts into our updated outlook, including this recent broker rate announcement.” The company is also preparing for further market complexity, including potential benefit reductions and service area changes by carriers, with the aim of leveraging its technology and broad carrier relationships to assist beneficiaries during enrollment season.
Management cited the company’s operational flexibility, strategic use of technology, and proactive adaptation to regulatory changes as key to Q2 results and the updated annual outlook.
eHealth’s forward guidance is underpinned by its ability to navigate regulatory disruptions, leverage technology in enrollment, and respond to industry changes in broker commission rates and carrier strategies.
Looking ahead, the StockStory team will focus on (1) how effectively eHealth navigates Medicare AEP disruptions and leverages its broad carrier relationships, (2) the impact of AI and technology-driven enhancements on call center productivity and member retention, and (3) execution of capital structure initiatives to maintain financial flexibility. Developments in regulatory policy and carrier strategies will also be critical to monitor.
eHealth currently trades at $3.46, up from $3.26 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Oct-18 | |
| Oct-15 | |
| Oct-12 | |
| Oct-07 | |
| Oct-07 | |
| Oct-07 | |
| Oct-03 | |
| Oct-03 | |
| Oct-02 | |
| Oct-01 | |
| Sep-29 | |
| Sep-25 | |
| Sep-16 | |
| Aug-27 | |
| Aug-21 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite